Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) EBT Margin (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed EBT Margin for 16 consecutive years, with 27.12% as the latest value for Q1 2026.

  • For Q1 2026, EBT Margin fell 3323.0% year-over-year to 27.12%; the TTM value through Mar 2026 reached 1.58%, down 1828.0%, while the annual FY2025 figure was 8.73%, 1519.0% down from the prior year.
  • EBT Margin hit 27.12% in Q1 2026 for Corcept Therapeutics, down from 4.9% in the prior quarter.
  • Across five years, EBT Margin topped out at 32.44% in Q3 2022 and bottomed at 27.12% in Q1 2026.
  • Average EBT Margin over 5 years is 18.89%, with a median of 23.84% recorded in 2024.
  • Year-over-year, EBT Margin soared 639bps in 2024 and then plummeted -3323bps in 2026.
  • Corcept Therapeutics' EBT Margin stood at 23.56% in 2022, then increased by 15bps to 27.18% in 2023, then plummeted by -35bps to 17.57% in 2024, then plummeted by -72bps to 4.9% in 2025, then tumbled by -653bps to 27.12% in 2026.
  • According to Business Quant data, EBT Margin over the past three periods came in at 27.12%, 4.9%, and 7.34% for Q1 2026, Q4 2025, and Q3 2025 respectively.